Difference between revisions of "Procarbazine (Matulane)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp")
 
(24 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood.  May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis.  May also directly damage DNA.<ref name="insert">[http://www.matulane.com/pdf/prescribe-info.pdf Procarbazine (Matulane) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/procarbazine.pdf Procarbazine (Matulane) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood.  May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis.  May also directly damage DNA.<ref name="insert">[http://www.matulane.com/pdf/prescribe-info.pdf Procarbazine (Matulane) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/procarbazine.pdf Procarbazine (Matulane) package insert (locally hosted backup)]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is used==
 +
*[[Anaplastic glioma]]
 +
*[[CNS lymphoma]]
 +
*[[Follicular lymphoma]]
 +
*[[Glioblastoma]]
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Low-grade glioma]]
 +
*[[Mantle cell lymphoma]]
 +
 
 +
==Diseases for which it was used==
 +
*[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]]
 +
*[[Non-small cell lung cancer - historical|Non-small cell lung cancer]]
 +
*[[Small cell lung cancer - historical|Small cell lung cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 10: Line 24:
 
*[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]</ref>
  
 +
==History of changes in FDA indication==
 +
* 1969-07-22: Initial FDA approval
 +
*Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV [[Classical Hodgkin lymphoma|Hodgkin's disease]]. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. ''(Based on Young et al. 1973a, Kolygin 1976, possibly others)''
 +
==History of changes in EMA indication==
 +
*1966-10-07: EURD
 
==Also known as==
 
==Also known as==
−
Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine, procarbazine HCl Chugaigai, procarbazine hydrochloride
+
*'''Code names:''' NCI-C01810, Ro 4-6467/1
 +
*'''Generic names:''' ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride
 +
*'''Brand names:''' Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Oral medications]]
 +
 +
[[Category:Triazenes]]
 +
[[Category:Alkylating agents]]
 +
[[Category:Human DNA synthesis inhibitors]]
 +
 +
[[Category:Anaplastic glioma medications]]
 +
[[Category:CNS lymphoma medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:Glioblastoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 +
[[Category:Low-grade glioma medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
 +
[[Category:Diffuse large B-cell lymphoma medications (historic)]]
 +
[[Category:Non-small cell lung cancer medications (historic)]]
 +
[[Category:Small cell lung cancer medications (historic)]]
 +
 +
[[Category:FDA approved in 1969]]
 +
[[Category:EMA approved in 1966]]
 +
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 12:14, 29 June 2024

General information

Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1969-07-22: Initial FDA approval
  • Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. (Based on Young et al. 1973a, Kolygin 1976, possibly others)

History of changes in EMA indication

  • 1966-10-07: EURD

Also known as

  • Code names: NCI-C01810, Ro 4-6467/1
  • Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride
  • Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine

References

  1. ↑ 1.0 1.1 Procarbazine (Matulane) package insert
  2. ↑ Procarbazine (Matulane) package insert (locally hosted backup)
  3. ↑ Procarbazine (Matulane) patient drug information (Chemocare)
  4. ↑ Procarbazine (Matulane) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Procarbazine_(Matulane)&oldid=87801"